Loading
Nanoplatforms for Cancer Theranostics · Journal article
Analytical Chemistry · August 12, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical probe development study demonstrating that NFK-(Azo)-DCM, an azoreductase-responsive NIR fluorescent probe, selectively activates and produces amplified signal in hypoxic cell lines and three murine disease models (LLC tumors, hindlimb ischemia, and ulcerative colitis). The work is mechanistic proof-of-concept and does not establish clinical utility, safety, or efficacy; it raises the hypothesis that such probes may enable real-time monitoring of hypoxia-associated pathologies.
Preclinical probe development and validation study combining in vitro confocal imaging and in vivo murine disease models. Cell lines: LLC, 4T1, HEK293. Animal models: LLC tumor-bearing mice, murine hindlimb ischemia, murine acute and chronic ulcerative colitis.. Intervention: NFK-(Azo)-DCM, an azoreductase-responsive near-infrared fluorescent self-assembled probe designed to activate under hypoxic conditions and AzoR overexpression.. Compared with: Negative controls (unspecified nature); untreated or vehicle-only groups implied but not detailed..
Confocal imaging showed statistically significant (P < 0.01) fluorescence enhancement in LLC, 4T1, and HEK293 cells under hypoxia In LLC tumor-bearing mice, probe produced 3.5-fold increase in NIR fluorescence signal in hypoxic tumor regions versus negative controls In murine hindlimb ischemia model, strong linear correlation between signal intensity and ischemic severity (R² > 0.9)
No information on probe biodistribution, clearance, toxicity, or off-target activation in vivo.
This probe is not yet ready for clinical application. The work establishes a mechanistic foundation and animal proof-of-concept for hypoxia imaging in three disease contexts; further preclinical validation of safety and specificity, followed by Phase 1 human studies, would be required to assess clinical potential.
This is a preclinical mechanistic study describing development and proof-of-concept validation of a novel imaging probe in cell culture and animal models; it does not test clinical utility, efficacy, or safety in humans.
As stated by the source record.
Quoted from the source exactly as published.
This probe is not yet ready for clinical application. The work establishes a mechanistic foundation and animal proof-of-concept for hypoxia imaging in three disease contexts; further preclinical validation of safety and specificity, followed by Phase 1 human studies, would be required to assess clinical potential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Azoreductase (AzoR) has emerged as a key player in reductive metabolism under hypoxia and a potential biomarker for hypoxia-associated pathologies, such as cancer and ulcerative colitis (UC). However, current clinical practice lacks a reliable method for real-time AzoR monitoring to effectively guide personalized therapies and assess treatment responses. We address this challenge by developing an AzoR-activatable near-infrared (NIR) fluorescent self-assembled probe, NFK-(Azo)-DCM, which combines self-assembly properties with hypoxia-specific activation through a rationally designed azobenzene unit. This molecular architecture enables a selective chemical transformation─the conversion of azobenzene to an electron-donating amino group under AzoR overexpression in hypoxic tissues─which initiates a cascade of NIR fluorescence signal amplification. Confocal imaging revealed that NFK-(Azo)-DCM exhibited statistically significant (P 0.01) fluorescence enhancement in LLC, 4T1, and HEK293 cells under hypoxic conditions. In LLC tumor-bearing mice, the probe produced a 3.5-fold increase in the NIR fluorescence signal specifically in hypoxic tumor regions compared to the negative controls, establishing its utility for tumor bioimaging. Most notably, in a murine hindlimb ischemia model, the probe achieved rapid and accurate detection of AzoR activity through its NIR emission, with a strong linear correlation between the signal intensity and ischemic severity (R2 0.9). The diagnostic versatility of NFK-(Azo)-DCM was further validated in both the acute and chronic UC models. These findings establish NFK-(Azo)-DCM as a dual-functional platform capable of noninvasive, real-time monitoring of hypoxia-related diseases, providing a promising method for advancing research in AzoR-associated pathologies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.